BioSpace News Archive

Skye Bioscience, Inc. (OTCQB: SKYE) (“the Company”), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system

Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the “Company”), a western Canadian-based life sciences company,

Pharma-Bio Serv, Inc. announced that revenues for the year ended October 31, 2023 were approximately $17.0 million, a decrease of approximately $2.4 million when compared to last year.

Eilean Therapeutics LLC today announced the clearance from the Human Research Ethics Committee in Australia to begin human dosing in the Phase 1 clinical program of eiletoclax, a highly potent and selective BCL2 inhibitor.

Copan Diagnostics, a leader in Clinical Microbiology automation solutions, has announced the third FDA clearance for its innovative pre-analytical processor, Colibrí™.

CNS Pharmaceuticals, Inc. announced the pricing of its “reasonable best efforts” public offering with participation from healthcare-focused institutional investors and certain officers and directors of the Company for the purchase and sale of 13,333,334 shares of common stock at a purchase price of $0.30 per share.

Beckman Coulter Diagnostics, a clinical diagnostics leader, will unveil its new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer, at Medlab Middle East in Dubai, taking place February 5-8, 2024.

HUTCHMED Limited announces that the marketing approval of ELUNATE® by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer.